Theralase Technologies Inc. V.TLT

Phase II Bladder Cancer Clinical Study (Pivotal)

[floatinketucky]

University Health Network (“UHN”)             Toronto, Ontario

London Health Sciences Centre (“LHSC”)  London, Ontario

Nova Scotia Health Authority (“NSHA”)       Halifax, Nova Scotia

University of British Columbia (“UBC”)        Vancouver, British Columbia

McGill University Health Centre (“MUHC”)    Montreal, Quebec




Virginia Urology (“VU”)                      Richmond, Virginia      

Urology Associates P.C. (“UA”)         Nashville, Tennessee    

 
MidLantic Urology (“MU”)                   Bala Cynwyd, Pennsylvania

Carolina Urolologic Research Centre (“CURC”)  Myrtle Beach, SC

[floatinketucky]

180 DAY ASSESSMENT Complete Response 45% To Be Determined 22% Partial Response 22% Non Responder 11%

[Oilminerdeluxe]

If the To be Determined cases can change to become Complete Response instead... Happy Days!! Speaking of that, Patient 13 and 14 was mentiond first time in a December 7 news release if memory recalls. So around beginning of March, they will have their 3 month check up. Presumably, these are the two who has gotten the correct treatment. Any chance they will let us know how that check up went? Or

[CancerSlayer]

  And even Happier Days if the partial & non responders can change to CRs after their second treatment : )

[Oilminerdeluxe]

Agree. Really hoping for the US sites to find people to treat shortly. That in itself should spring life into the company and its shareholders. Whatever the deal with dr. Coombs is, I hope they will update us on that too asap. Seems like a nice fellow. He appears to reply to e-mails if questions are asked.

[floatinketucky]

Shawn Shirazi PhD, Chief Executive Officer, Theralase®, stated, "Another milestone has been reached by the Company with the addition of MU in Pennsylvania as a clinical study site. Theralase is focused on its target of enrolling and treating 11 additional patients in early 2021 for a total of 25 patients for potential Breakthrough Designation Approval and approximately 100 patients in